288 related articles for article (PubMed ID: 26993758)
1. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Cortes JE; Lipton JH; Miller CB; Busque L; Akard LP; Pinilla-Ibarz J; Keir C; Warsi G; Lin FP; Mauro MJ
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):286-96. PubMed ID: 26993758
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
Cony-Makhoul P; Gardembas M; Coiteux V; Carpentier N; Pommier C; Violet I; Quittet P; Berger MG;
Br J Haematol; 2018 Feb; 180(3):356-364. PubMed ID: 29265184
[TBL] [Abstract][Full Text] [Related]
3. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y
Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980
[TBL] [Abstract][Full Text] [Related]
5. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
Miyamura K; Miyamoto T; Tanimoto M; Yamamoto K; Kimura S; Kawaguchi T; Matsumura I; Hata T; Tsurumi H; Saito S; Hino M; Tadokoro S; Meguro K; Hyodo H; Yamamoto M; Kubo K; Tsukada J; Kondo M; Aoki M; Okada H; Yanada M; Ohyashiki K; Taniwaki M
Leuk Res; 2016 Dec; 51():11-18. PubMed ID: 27771544
[TBL] [Abstract][Full Text] [Related]
6. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
[TBL] [Abstract][Full Text] [Related]
7. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Cortes JE; Hochhaus A; le Coutre PD; Rosti G; Pinilla-Ibarz J; Jabbour E; Gillis K; Woodman RC; Blakesley RE; Giles FJ; Kantarjian HM; Baccarani M
Blood; 2011 May; 117(21):5600-6. PubMed ID: 21467546
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
Kim DW; Saussele S; Williams LA; Mohamed H; Rong Y; Zyczynski T; Pinilla-Ibarz J; Abruzzese E
Ann Hematol; 2018 Aug; 97(8):1357-1367. PubMed ID: 29556695
[TBL] [Abstract][Full Text] [Related]
12. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
13. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
[TBL] [Abstract][Full Text] [Related]
15. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Guérin A; Chen L; Ionescu-Ittu R; Marynchenko M; Nitulescu R; Hiscock R; Keir C; Wu EQ
Curr Med Res Opin; 2014 Nov; 30(11):2317-28. PubMed ID: 25025755
[TBL] [Abstract][Full Text] [Related]
16. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
17. Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.
Ailawadhi S; Akard LP; Miller CB; Jillella A; DeAngelo DJ; Ericson SG; Lin F; Warsi G; Radich J
Ther Adv Hematol; 2017 Jan; 8(1):3-12. PubMed ID: 28042454
[TBL] [Abstract][Full Text] [Related]
18. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G
Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Giles FJ; le Coutre PD; Pinilla-Ibarz J; Larson RA; Gattermann N; Ottmann OG; Hochhaus A; Radich JP; Saglio G; Hughes TP; Martinelli G; Kim DW; Novick S; Gillis K; Fan X; Cortes J; Baccarani M; Kantarjian HM
Leukemia; 2013 Jan; 27(1):107-12. PubMed ID: 22763385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]